Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried?

Eli Lilly reported stellar fourth-quarter 2025 revenue of $19.3 billion, a 43% year-over-year increase driven largely by GLP-1 products: Mounjaro sales rose 110% to $7.4 billion and Zepbound jumped 123% to nearly $4.3 billion, with the two drugs combining for $11.7 billion — over 60% of revenue. The company carries a roughly $950 billion market cap and trades at a high P/E of ~46, pricing substantial future growth, while management and analysts caution that intensifying competition in the GLP-1 space and revenue concentration pose short-term downside risks despite attractive long-term growth prospects.

Analysis

Market structure: Eli Lilly (LLY) is the dominant near-term winner — Mounjaro + Zepbound = ~$11.7B Q4 sales (~60% of revenues) and support outsized free-cash flow that justifies a premium today (market cap ≈ $950B, trailing P/E ≈46). Losers include smaller GLP-1 entrants and payers facing higher short-run drug spend; contract manufacturers and AAV/device suppliers are secondary winners from capacity demand. The key structural risk is revenue concentration: a 10–30% market-share swing to competitors within 2–3 years would meaningfully compress LLY’s valuation.

Competitive dynamics and supply/demand: Demand for GLP-1 class is strong and sticky (chronic use), but manufacturing capacity and injector supply constraints create a short-to-medium-term supply bottleneck that supports pricing. Over 12–36 months, expect accelerating entrant launches and payer negotiations to exert 10–25% downward price/mix pressure on unit economics absent label or adherence advantages. This will shift share over time to firms with scaled production and broader payer contracts.

Risk assessment: Tail risks include aggressive US/Europe pricing reforms, class-wide label restrictions, or an unexpected manufacturing failure at a key CMO — any could trigger >25% downside in 3–12 months. Hidden dependencies: LLY’s growth assumes uninterrupted CMO capacity, steady insurance reimbursement, and no major adverse-event safety signals; each is a 6–18 month catalyst. Watch patent expiries and clinical readouts from key competitors as 12–36 month reversal points.

Contrarian/valuation angle: Consensus may understate LLY’s execution moat (real-world adherence and combination-label advantages) and overstate near-term share loss; conversely, current premium prices a low-probability ‘best-case’ outcome. Historical parallel: dominance cycles in high-margin specialty drugs (e.g., HIV protease inhibitors) show multiyear leadership can persist despite entrants. A calibrated exposure using options and pair trades captures upside while bounding valuation risk.

Key Decisions for Investors

• If overweight LLY (>4% portfolio), trim to 2–3% within 1–4 weeks and realize gains; high P/E (≈46) + 60% revenue concentration justifies reduced position size ahead of competitor launches over next 12–24 months.
• Establish protective hedges: buy a 6–12 month put spread sized to cover 1–2% of portfolio (example: buy 30% OTM 12‑month put, sell 45% OTM put) to cap ~20–30% downside while paying <1.5% of portfolio in premium.
• Use option income to monetize upside: sell 3-month covered calls at ~10% above current spot (or call spreads if unassigned) to generate yield while keeping upside optionality; roll as necessary every quarter.
• Implement a pair trade (6–18 months): long contract-manufacturing exposure (e.g., CTLT or TMO, 1–2% position) to capture capacity tailwinds, paired with a 1% short or synthetic short of LLY to express valuation risk if payer/pricing headwinds materialize.
• Trigger-based rules: add to LLY (up to +1–1.5% portfolio) only on a pullback ≥20% from current levels or after 2 sequential quarters of sustained >20% YOY unit growth with no margin deterioration; else keep exposure capped.